Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients

American Journal of Hematology

Volumn 88, Issue 1, 2013, Pages 10-15

  Kim, Inho ^a,c   Koh, Youngil ^a,c   Yoon, Sung Soo ^a   Park, Seonyang ^a   Kim, Byoung Kook ^a   Kim, Dae Young ^b   Lee, Jung Hee ^b   Lee, Kyoo Hyung ^b   Cheong, June Won ^c   Lee, Hong Kee ^d   Kim, Sung Hyun ^e   Kim, Hyuk ^f   Joo, Young Don ^g   Lee, Sang Min ^g   Won, Jong Ho ^h   Park, Sung Kyu ^h   Hong, Dae Sik ^h   Kim, Se Hyung ^h   Sohn, Sang Kyun ⁱ   Kim, Chul Soo ^j   Park, Eunkyung ^k   Kim, Min Kyoung ^l   Park, Moo Rim ^m   Lee, Je Hwan ^b   Min, Yoo Hong ^c   more..

^a Seoul National University Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Konkuk University Hospital   (South Korea)

^e Dong A University College of Medicine   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g Inje University College of Medicine   (South Korea)

^h Soonchunhyang University College of Medicine   (South Korea)

ⁱ Kyungpook National University Hospital   (South Korea)

^j Inha University Hospital   (South Korea)

^k Chung Ang University College of Medicine   (South Korea)

^l Yeungnam University Hospital   (South Korea)

^m Wonkwang University Hospital   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYTARABINE; FLUDARABINE; IDARUBICIN; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE MARROW EXAMINATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CHEMOTHERAPY INDUCED EMESIS; COMORBIDITY; CONSOLIDATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HYPERBILIRUBINEMIA; INDUCTION CHEMOTHERAPY; INFECTION; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SKIN DISEASE; STOMATITIS; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; COHORT STUDIES; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL RATE; TIME FACTORS; VIDARABINE;

EID: 84871445452     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23337     Document Type: Article

References (44)

1. Derolf AR, Kristinsson SY, Andersson TM, et al. Improved patient survival for acute myeloid leukemia: A population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 2009; 113: 3666-3672.
2. Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood 2012; 120: 1993-2002.
3. Dombret H, Raffoux E, Gardin C. New insights in the management of elderly patients with acute myeloid leukemia. Curr Opin Oncol 2009; 21: 589-593.
4. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: A review. Br J Haematol 2011; 152: 524-542.
5. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.
6. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 2002; 52: 363-371.
7. Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999; 17: 3569-3576.
8. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323-3329.
9. Laupeze B, Amiot L, Drenou B, et al. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol 2002; 116: 834-838.
10. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol: Off J Am Soc Clin Oncol 2010; 28: 562-569.
11. Vey N, Coso D, Bardou VJ, et al. The benefit of induction chemotherapy in patients age > or = 75 years. Cancer 2004; 101: 325-331.
12. Milligan DW, Grimwade D, Cullis JO, et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006; 135: 450-474.
13. Ferrara F, D'Arco AM, De Simone M, et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia. Haematologica 2005; 90: 776-784.
14. Borthakur G, Kantarjian H, Wang X, et al. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 2008; 113: 3181-3185.
15. Clavio M, Vignolo L, Albarello A, et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: Results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 2007; 138: 186-195.
16. Russo D, Pricolo G, Michieli M, et al. Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia. Leuk Lymph 2001; 40: 335-343.
17. Higashi Y, Turzanski J, Pallis M, Russell NH. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia. Br J Haematol 2000; 111: 565-569.
18. Russo D, Malagola M, de Vivo A, et al. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. Br J Haematol 2005; 131: 172-179.
19. Archimbaud E, Jehn U, Thomas X, et al. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia 1999; 13: 843-849.
20. IARC. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer (IARC); 2008.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Disease 1987; 40: 373-383.
22. Montesinos P, Rayon C, Vellenga E, et al. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 2011; 117: 1799-1805.
23. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312-1320.
24. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: A trial by the Eastern Cooperative Oncology Group. Blood 2004; 103: 479-485.
25. Estey E. AML in older patients: Are we making progress? Best Pract Res Clin Haematol 2009; 22: 529-536.
26. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007; 25: 1908-1915.
27. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: A review. Br J Haematol; 152: 524-542.
28. Harousseau JL, Martinelli G, Jedrzejczak WW, et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 2009; 114: 1166-1173.
29. Nand S, Godwin J, Smith S, et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: Results from a pilot trial. Leuk Lymph 2008; 49: 2141-2147.
30. Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998; 16: 872-881.
31. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302-1311.
32. Juliusson G, Hoglund M, Karlsson K, et al. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol 2003; 123: 810-818.
33. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361: 1235-1248.
34. Giles F, Rizzieri D, Karp J, et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 2007; 25: 25-31.
35. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010; 28: 549-555.
36. Chauncey TR, Gundacker H, Shadman M, et al. Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. Br J Haematol 2010; 148: 48-58.
37. Agura E, Cooper B, Holmes H, et al. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist 2011; 16: 197-206.
38. Schaich M, Harbich-Brutscher E, Pascheberg U, et al. Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome. Haematologica 2002; 87: 455-464.
39. Malagola M, Damiani D, Martinelli G, et al. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. Br J Haematol 2007; 136: 87-95.
40. Etienne A, Esterni B, Charbonnier A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007; 109: 1376-1383.
41. Harb AJ, Tan W, Wilding GE, et al. Treating octogenarian and nonagenarian acute myeloid leukemia patients-Predictive prognostic models. Cancer 2009; 115: 2472-2481.
42. Sonneveld P, Wiemer E. Assays for the analysis of P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts. Leukemia 1997; 11: 1160-1165.
43. Kyle-Cezar F, Echevarria-Lima J, dos Santos Goldenberg RC, Rumjanek VM. Expression of c-kit and Sca-1 and their relationship with multidrug resistance protein 1 in mouse bone marrow mononuclear cells. Immunology 2007; 121: 122-128.
44. Blair A, Sutherland HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol 2000; 28: 660-671.